Drug Profile
Olutasidenib - Forma Therapeutics
Alternative Names: FT 2102Latest Information Update: 18 Dec 2019
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Class Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Yes - Acute myeloid leukaemia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Glioma; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 09 Dec 2019 Updated positive efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndrome presented at the American Society of Haematology (ASH-2019)
- 07 Dec 2019 Updated efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndrome presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
- 29 Nov 2019 Updated efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndromes released by FORMA Therapeutics